Last week, the U.S. Food and Drug Administration (“FDA”) rung in the new year with a flurry of device-related activity, updating two final guidance documents and withdrawing a guidance published back in 2017. The two final guidance documents released on January 6, 2026 pertain to (1) General Wellness Devices and (2) Clinical Decision Support Software, and supersede previous versions of those guidance documents.[1] Then on January 7, 2026, FDA withdrew its guidance entitled “Software as a Medical Device (SAMD): Clinical Evaluation.”[2]
Latest Post
More Posts
FDA Continues Crack Down on DTC Advertising: Untitled Letter Highlights Pitfalls in Schizophrenia Drug Promotion
What to Watch: Continued DTC Advertising Enforcement
Congress Joins the Biomanufacturing Onshoring Party
Texas Sues Johnson & Johnson and Kenvue Over Tylenol: Scientific Evidence, Regulatory Shifts, and the Future of OTC Drug Labeling
What to Watch: Human Cell and Tissue Product Regulation
FDA Touts Continued Commitment to Cell and Gene Therapy Products through Trio of Guidances
FDA’s Wave of Untitled Letters Signals Stricter Scrutiny for DTC Pharma Ads
FDA Unleashes Wave of Enforcement: The Industry Faces a Crackdown on Drug Advertising
FDA’s Vast Ad/Promo Warning – Enforcement Ramp-Up or PR Nothingburger?
Subscribe: Subscribe via RSS